Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esketamine + propofol
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of esketamine and propofol used for procedural sedation and analgesia. This combination leverages the dissociative anesthetic and analgesic properties of esketamine with the sedative-hypnotic effects of propofol. The combination reduces propofol consumption, decreases the incidence of hypotension and bradycardia, and provides more stable hemodynamics compared to propofol alone or other sedative combinations.
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)HCN1 (Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on esketamine + propofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esketamine + propofol.